Clinical trials: Bone Marrow Transplantation, open to volunteers
Solid Organ Transplantation, Bone Marrow Transplantation
Biomarkers in Transplant Recipients to Improve Outcomes
The objective of this study is to evaluate whether certain proteins, expressed in biological tissues can indict a better understanding of the effect of drugs that are used to treat rejection, and of processes leading to rejection…
- Trial name
- NCT01163578
- Where
- United States
- Volunteers
- 1,200 people
- Sponsor
- University of Pittsburgh
Bone Marrow Transplantation, AML
Model-Informed Precision Dosing on Cyclosporine Therapy in Hematopoietic Stem Cell Transplant Recipients
The purpose of this study is to develop a new tool that helps doctors choose the right cyclosporine dose for patients undergoing bone marrow transplantation.
- Trial name
- NCT07695571
- Volunteers
- 300 people
- Sponsor
- Yasmin medhat munir Mohamed
Graft-Versus-Host Disease(GVHD), Bone Marrow Transplantation
Low-Dose ATG/PTCy Plus Ivarmacitinib for aGVHD Prevention in Haplo-PBSCT From Parous Female Donors
Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), significantly affecting survival and quality of life.
- Trial name
- PARITY (NCT07570745)
- Testing
- Low-dose ATG + PTCy + Ivarmacitinib
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Acute Graft-versus-host Disease, Allogeneic Bone Marrow Transplantation
MAGIC Ruxolitinib for aGVHD
This clinical trial will study ruxolitinib-based treatment of acute graft-versus-host-disease (GVHD) that developed following allogeneic hematopoietic cell transplant.
- Conditions
- Acute Graft-versus-host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects
- Trial name
- MAGIC V (NCT06936566)
- Testing
- Ruxolitinib, Methylprednisolone
- Where
- 14 sites in United States
- Volunteers
- 98 people
- Sponsor
- John Levine
Allogenic Bone Marrow Transplantation
Rehab Study for alloBMT Patients
The goals of this phase III clinical trial is to determine effectiveness in the setting where it will be implemented as well as to gain an understanding of the context for implementation.
- Trial name
- CaRE-4-alloBMT (NCT07457866)
- Testing
- CaRE-4-alloBMT
- Where
- Canada
- Volunteers
- 208 people
- Sponsor
- Jennifer Jones
Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL, Infants With Very High Risk KMT2A B-ALL
Orphan Indications for CD19 Redirected Autologous T Cells
This is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19 in pediatric and young adult patientswith hypodiploid (Cohort A) or t(17;19) B-ALL (Cohort B), infants with very high risk KMT2A B-ALL (Cohort…
- Conditions
- Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL, Infants With Very High Risk KMT2A B-ALL, Patients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation
- Trial name
- NCT04276870
- Testing
- Murine CART19
- Where
- United States
- Volunteers
- 133 people
- Sponsor
- Stephan Grupp MD PhD
Multiple Myeloma, Acute Myeloid Leukemia
National Longitudinal Cohort of Hematological Diseases
Background Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China.
- Conditions
- Multiple Myeloma, Acute Myeloid Leukemia, Hemophilia, Hemophilia A
- Trial name
- NICHE (NCT04645199)
- Where
- China
- Volunteers
- 2,300 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hematopoietic Stem Cell Transplantation (HSCT), Acute Myeloid Leukemia (AML)
High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
The High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) study is the first prospective real-world cohort of hematologic diseases and transplantation in the Qinghai-Tibet Plateau.
- Conditions
- Hematopoietic Stem Cell Transplantation (HSCT), Acute Myeloid Leukemia (AML), Leukemias, Acute Myeloid, Myeloid Leukemias, Acute
- Trial name
- HALO-SCT (NCT07205523)
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Yigeng Cao,MD,PhD